5-iodo-6-methyl-N4-pentylpyrimidine-2,4-diamine | 1158803-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 5-iodo-6-methyl-N4-pentylpyrimidine-2,4-diamine
• 英文别名: 5-iodo-6-methyl-4-N-pentylpyrimidine-2,4-diamine
• CAS: 1158803-88-3
• 化学式: C₁₀H₁₇IN₄
• 分子量: 320.176
• InChiKey: KKBMHAOZAZSWPX-UHFFFAOYSA-N

物化性质

• 沸点：
  447.3±55.0 °C(predicted)
• 密度：
  1.585±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-iodo-6-methyl-N4-pentylpyrimidine-2,4-diamine 、 4-(2-丙炔-1-基)吗啉 在 copper(l) iodide 、 四(三苯基膦)钯 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 benzyl 4-(2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)but-3-ynylcarbamate
  参考文献：
  名称：

  [EN] PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS
  [FR] DÉRIVÉS DE PYRIMIDINE POUR LE TRAITEMENT DE L'ASTHME, DE LA BRONCHO-PNEUMOPATHIE CHRONIQUE OBSTRUCTIVE (COPD), DE LA RHINITE ALLERGIQUE, DE LA CONJONCTIVITE ALLERGIQUE, DE LA DERMATITE ATOPIQUE, DU CANCER, DE L'HÉPATITE B, DE L'HÉPATITE C, DU VIH, DU

  摘要：

  本发明提供了式（I）中的化合物，其中R1、R2、R3和R4如规范中定义，以及其药用盐，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。

  公开号：

  WO2009067081A1
• 作为产物：
  描述：

  2-氨基-4-氯-6-甲基嘧啶 在 N-碘代丁二酰亚胺 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 5-iodo-6-methyl-N4-pentylpyrimidine-2,4-diamine
  参考文献：
  名称：

  Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines

  摘要：

  Activation of human toll-like receptor-8 (TLR8) evokes a distinct cytokine profile favoring the generation of Type 1 helper T cells. A multiplexed high-throughput screen had led to the identification of N-4-butyl-5-iodo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agonist, and a detailed structure-activity relationship study of this chemotype was undertaken. A butyl substituent at N-4 was optimal, and replacement of the 5-iodo group with chloro, bromo, or fluoro groups led to losses in potency, as did the introduction of aromatic bulk. Drawing from our previous structure-based design, several 5-alkylamino derivatives were evaluated. Significant enhancement of potency was achieved in 5-(4-aminobutyl)-N-4-butyl-6-methylpyrimidine-2,4-diamine. This compound potently induced Th1-biasing IFN-gamma And IL-12 in human blood, but lower levels of the proinflammatory cytokines IL-1 beta, IL-6, and IL-8. These results suggest that the inflammatory and reactogenic propensities of this compound could be considerably more favorable than other TLR8 agonists under evaluation.

  DOI：

  10.1021/acs.jmedchem.6b00872

文献信息

• PYRIMIDINES AND USES THEREOF
  申请人：David Sunil Abraham

  公开号：US20180215720A1

  公开（公告）日：2018-08-02

  The various examples presented herein are directed to compounds of the Formula: wherein R 1 -R 5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.

  本文提供的各种示例是针对下述公式的化合物的：其中R1-R5在此处被定义，并且这些化合物的用途包括在其他方面抑制受试者的免疫反应。
• Compounds
  申请人：AstraZeneca AB

  公开号：US08268990B2

  公开（公告）日：2012-09-18

  The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式(I)中的化合物，其中R1、R2、R3和R4如规范中所定义，并且其药学上可接受的盐，以及其制备过程，包含它们的制药组合物和它们在治疗中的使用。
• NOVEL COMPOUNDS
  申请人：Bennett Nicholas J.

  公开号：US20130045955A1

  公开（公告）日：2013-02-21

  The present invention provides compounds of formula (I) herein R 1 , R 2 , R 3 and R 4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了公式（I）的化合物，其中R1、R2、R3和R4如规范中所定义，并且其药学上可接受的盐，以及它们的制备方法，含有它们的制药组合物和它们在治疗中的使用。
• Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers
  申请人：Bennett Nicholas J.

  公开号：US08765939B2

  公开（公告）日：2014-07-01

  The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式(I)化合物，其中R1、R2、R3和R4如规范中所定义，以及其药学上可接受的盐，以及制备它们的方法，含有它们的制药组合物以及它们在治疗中的用途。
• Novel Compounds
  申请人：BENNETT Nicholas J.

  公开号：US20090209524A1

  公开（公告）日：2009-08-20

  The present invention provides compounds of formula (1) wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（1）的化合物 其中R1、R2、R3和R4如规范中所定义，并且其药学上可接受的盐，以及制备它们的方法，含有它们的制药组合物以及它们在治疗中的使用。